By Category
by this agency in this category 222 findings drawn from 198 published documents. The most recent cases are below; the full set is in search.
See all Health Canada Labeling and packaging findingsThe positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.
See every finding in this document View the regulator's official sourceThe importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).
View the regulator's official sourceThe importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).
View the regulator's official sourceThe handling of standard operating procedures for good manufacturing practices was inadequate. The quality agreement outlining the responsibilities for fabricating, packaging or labelling, and/or testing was inadequate.
See every finding in this document View the regulator's official sourceThe importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).
See every finding in this document View the regulator's official sourceThe positive identification of each batch of drug after the packaging and/or after it was received on the importer's premises was inadequate.
View the regulator's official sourceThese findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-10-20, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.
Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.
Click the confirmation button in the email. It's sent from GRM Solutions Brief. If you don't see it, check your spam folder.
Growth stages previewSolve a quiz to start hatching
Your growth record is stored safely in this browser.
